Rodman & Renshaw Reiterates “Neutral” Rating for Viracta Therapeutics (NASDAQ:VIRX)

Rodman & Renshaw reiterated their neutral rating on shares of Viracta Therapeutics (NASDAQ:VIRX) in a research note published on Friday morning,Benzinga reports. Rodman & Renshaw currently has a $0.25 price objective on the stock, down from their prior price objective of $3.50.

Separately, Royal Bank of Canada cut their target price on shares of Viracta Therapeutics from $4.00 to $2.00 and set an “outperform” rating on the stock in a research note on Thursday, November 14th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, Viracta Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $4.05.

Viracta Therapeutics Price Performance

Shares of NASDAQ VIRX opened at $0.16 on Friday. The company has a market cap of $6.36 million, a price-to-earnings ratio of -0.15 and a beta of 0.67. The stock’s 50-day moving average is $0.19 and its two-hundred day moving average is $0.31. Viracta Therapeutics has a 1-year low of $0.13 and a 1-year high of $1.31.

Institutional Trading of Viracta Therapeutics

A hedge fund recently bought a new stake in Viracta Therapeutics stock. Stonepine Capital Management LLC bought a new position in shares of Viracta Therapeutics, Inc. (NASDAQ:VIRX) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 500,000 shares of the company’s stock, valued at approximately $116,000. Stonepine Capital Management LLC owned approximately 1.27% of Viracta Therapeutics as of its most recent filing with the SEC. 31.37% of the stock is owned by institutional investors and hedge funds.

Viracta Therapeutics Company Profile

Viracta Therapeutics, Inc, a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.